Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

WuXi PharmaTech Licenses OMT’s OmniRat to Aid Biologic Drug Discovery

publication date: Sep 5, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
WuXi PharmaTech and Open Monoclonal Technology of California reached an agreement that allows WuXi to use OMT's OmniRat, a transgenic rat, to develop therapeutic antibody candidates for WuXi's clients. According to the two companies, OmniRat generates fully human antibodies with great specificity, affinity and manufacturability. It eliminates time-consuming humanization of traditional mouse-derived antibodies and the need for optimization of lead candidates using phage display technology. More details....

Stock Symbol: (NYSE: WX)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners